(UroToday.com) The ASCO 2020 virtual education program featured a session on recent advances in nuclear medicine theranostics for cancer. As part of this session, Jonathan McConathy, MD, Ph.D., provided an introductory presentation to theranostics. The term ‘theranostic’ is derived from ‘therapeutic plus diagnostic’, which is a diagnostic test to stratify patients by likelihood to respond to a specific treatment, or to monitor early response to treatment and predict efficacy.